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Transportability proﬁleAbstract The main objective of the present study was to develop quantitative-structure property
relationship (QSPR) models with predictability for release, transportability and related properties
of formulation containing a neutral drug (glimepiride) based on polymeric properties. Such physic-
ochemical properties are measure of polymers’ behavior in deciding release, transportability and
bioavailability of drug. Therefore comprehensive study of properties could help in deciding proper
polymer composite for formulation with required characteristics. A total of nine glimepiride
(GLMP) tablet batches were prepared using three polymers representing extended, moderate and
immediate release categories. Molecular descriptors were calculated from polymeric structures
and correlated with formulation characteristics. This leads to generation of predictive models.
Compatibility between drug-excipients was conﬁrmed. Weight uniformity, drug content, hardness
and friability tests showed acceptable results. In vitro dissolution kinetics exhibited Korsmeyer-
peppas model as best ﬁt. Best correlation coefﬁcient and validation of developed QSPRs showed
powerful predictability for properties. Transportability was inﬂuenced by release rate together with
molecular size, pKa, log P and water solubility of GLMP. Generated models were found to signif-
icantly predict the release, transportability and related formulation properties. QSPR models were
developed with enough prediction potential for the properties of formulation containing any neutral91 231
S1916 V.L. Gaikwad et al.drug and could also help to decide the formulation composition for required characteristics together
with pharmacoeconomic impact with respect to time, cost and material.
ª 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of King Saud University. This is
an open access article under theCCBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Polymeric excipients are commonly incorporated in the formu-
lation for attaining a site speciﬁc delivery of the drug in more
controlled and effective way along with the improved physical
appearance of formulation and drug protection from biologi-
cal media before its release (Ariﬁn et al., 2006; Langer and
Peppas, 1983; Borgquist et al., 2006). Therefore, physicochem-
ical properties of polymer as indicative of its wettability and
hence the drug dissolution, must be studied extensively before
selection of any polymer for desired drug delivery system
(Grover et al., 2000a, 2000b). By using QSPR approach such
physicochemical properties or descriptors representing poly-
mer structure can also be calculated theoretically and can be
subsequently correlated with formulation characteristics
(Grover et al., 2000a, 2000b; Gafourian et al., 2007). This
could help in the development of QSPR models with potential
predictability for required property based on polymeric prop-
erties showing signiﬁcant inﬂuence on formulation characteris-
tics (Wu et al., 2005). Developed model could help in deciding
and optimizing the appropriate polymer composite and hence
the formulation composition with required characteristics
(Siepmann et al., 2010). Moreover, the release, transportability
and related formulation properties would also become pre-
dictable theoretically for other drugs from the neutral class
and from other polymers with matching physicochemical
properties (Gafourian et al., 2007). Therefore, QSPR approach
will help in the future formulation development work through
the deciding composition of formulation in a more systematic
and theoretical way for desired characteristics with saving of
time and cost of pharmaceutical industry (Ariﬁn et al., 2006;
Gaikwad and Bhatia, 2013; Wu et al., 2005).
The present study was designed with the main objective to
develop a predictive mathematical model through correlation
analysis between polymeric descriptors and properties of a for-
mulation containing a neutral drug. A total of nine tablet
batches of GLMP (model drug from neutral class) were pre-
pared using three polymers representing synthetic or cellulose
semi-synthetic class from each extended, moderate and imme-
diate release category. Prepared compacts were further evalu-
ated for several post-compression properties such as
compatibility, weight uniformity, drug content, hardness, fri-
ability and in vitro drug release and transportability studies.
2. Materials and methods
2.1. Materials
GLMP was a generous gift from USV Limited (Mumbai,
Maharashtra, India). Evonik industries (Mumbai,
Maharashtra, India) provided Eudragit RS100 (ERS100) as
a gift sample. Methocel E15 LV premium (ME15) and
Ethocel 10 cp FP standard premium with 48.0–49.5% ethoxylcontent (EC10) were kindly obtained from Colorcon Asia Pvt.
Ltd. (Goa, India) as gift samples. Hydroxypropyl cellulose
(HPC, Innovative Chemicals, Mumbai, Maharashtra, India);
Crospovidone (CPVP, S.D. Fine-Chem Ltd., Mumbai,
Maharashtra, India); Croscarmellose sodium (CCS, S.D.
Fine-Chem Ltd., Mumbai, Maharashtra, India); Sodium
starch glycolate (SSG, S.D. Fine-Chem Ltd., Mumbai,
Maharashtra, India); Polyethylene glycol 6000 (PEG 6000,
Research Lab, Mumbai, Maharashtra, India);
Carboxymethyl cellulose sodium (CMCS, Loba Chemie Pvt.
Ltd., Mumbai, Maharashtra, India) were purchased.
Research Lab (Mumbai, Maharashtra, India) supplied starch,
lactose, fumed silica and magnesium stearate. HiMedia
Laboratories Pvt. Ltd. (Mumbai, Maharashtra, India) sup-
plied dialysis membrane (Dialysis Membrane – 110). All other
ingredients and chemicals used were of analytical grade or
higher.
2.2. Methods
2.2.1. Characterization of drug and excipients
2.2.1.1. Standard curve. GLMP identiﬁcation was done within
scanning range of 200–400 nm by using UV–Visible spec-
trophotometer (Shimadzu Corporation, UV-1800, Japan). A
standard curve was obtained separately in hydrochloric acid
buffer pH 1.2 USP (USPNF, 1995) and phosphate buffer
pH 6.8 USP (USPNF, 1995) at observed kmaxs for GLMP.
2.2.1.2. Fourier transform infrared spectroscopy (FTIR) stud-
ies. Compatibility testing between pure drug (GLMP) and
other excipients was accomplished by using recording Jasco
FTIR-4100 Spectrometer within scanning range of
400–4000 cm1 at a resolution of 1 cm1. FTIR analysis was
done using a KBr method (1:100; sample:KBr ratio) to exam-
ine any chemical or structural changes in GLMP in tablet
formulations.
2.2.2. Formulation of compacts
As per composition shown in Table 1, a total of nine batches
of GLMP granules (GMR1 to GMO3) was prepared by wet
granulation technique. Initially uniformly sized powder mass
was obtained by sieving all ingredients separately through a
mesh with 180 lm size (ASTM #80). Further distilled water
was added as a granulating liquid to convert uniformly mixed
powdered mass into wet mass (except batch GMB2 and
GMO3). The wet mass was passed through mesh size 850 lm
(ASTM #20) to obtain granules which were further dried in
a hot air oven (Bio Technics India, Mumbai, Maharashtra,
India) at 60 C for 1 h. After drying, the granules with narrow
size distribution were selected by passing through mesh size
600 lm (ASTM #30) and subsequently mixed with glidant
(fumed silica or aerosil) and lubricant (magnesium stearate)
for compression into tablets.
Table 1 Composition of GLMP tablet formulations.a
Ingredients Batch code
GMR1 GMR2 GMR3 GMB1 GMB2 GMB3 GMO1 GMO2 GMO3
SSG 300 – – – – – – – –
CCS – 300 – – – – – – –
CPVP – – 300 – – – – – –
ME15 – – – 300 – – – – –
PEG 6000 – – – – 300 – – – –
CMCS – – – – – 300 – – –
EC10 – – – – – – 300 – –
HPC – – – – – – – 300 –
ERS100 – – – – – – – – 300
Aerosil 13 13 13 13 13 13 13 13 13
Magnesium Stearate 25 25 25 25 25 25 25 25 25
Lactose 23 23 23 23 23 23 23 23 23
Starch 35 35 35 35 35 35 35 35 35
Total weight of compact (mg) 400 ± 5 400 ± 5 400 ± 5 400 ± 5 400 ± 5 400 ± 5 400 ± 5 400 ± 5 400 ± 5
a All quantities are given in mg. Each tablet contains 4 mg of GLMP.
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pared by compressing the dried granules [400 ± 5 mg contain-
ing 4 mg of GLMP (IP, 2010a; Reichal et al., 2011; Patel et al.,
2012; Choudhary and Bajpai, 2011)] by using a 8-punch rotary
tablet press machine (CIP Machineries Pvt. Ltd., Ahmadabad,
Gujarat, India) having a 10-mm round, ﬂat-faced punch and
die set. Tablets were further kept at ambient conditions for
the 24 h relaxation period for elastic recovery and hardening
effect (Krycer et al., 1982). Subsequent to relaxation period
tablets from all batches were characterized for various post-
compression evaluation parameters: drug content, weight uni-
formity, diameter, thickness, friability, hardness and in vitro
dissolution and transportability studies.
2.2.3. Evaluation of tablet formulations
2.2.3.1. Weight uniformity. By using an electronic balance
(AUX220, Shimadzu Corporation, Japan) a total of randomly
selected 20 tablets for each batch (GMR1 to GMO3) were
weighed separately and compared with average weight for
calculation of % deviation. Tablets comply with the weight
uniformity test if not more than two of the individual
tablet weights deviate from the average weight by more than
±5% (for 250 mg or more) (IP, 2010b; Banker and
Anderson, 1987).
2.2.3.2. Drug content. For estimation of GLMP content, weigh
and powder not less than 10 tablets individually from each
batch (GMR1 to GMO3). Accurately weigh a quantity of
powder equivalent to 4 mg of GLMP (tablet dose) and dissolve
in sufﬁcient amount of methanol and volume was made up to
100 mL with phosphate buffer pH 6.8 USP (Wagh et al., 2012;
Sahu, 2010). The resulting solution was ﬁltered using
Whatman ﬁlter paper no. 42 and after suitable dilutions, ana-
lyzed by UV–Visible double beam spectrophotometer
(Shimadzu Corporation, UV-1800, Japan) at 227 nm against
methanol:phosphate buffer pH 6.8 USP as a blank. The
GLMP content of the tablet was further determined using
the linearity equation obtained from the calibration curve.
Drug content of all tablet formulations was tested in triplicate
(n = 3) (Wagh et al., 2012; Sahu, 2010).2.2.3.3. Hardness. Hardness or crushing force required to
break the compact was determined by using Monsanto-type
hardness tester (Lab Hosp Corporation, Mumbai,
Maharashtra, India) for not less than 3 tablets from each batch
(GMR1 to GMO3). Tablet hardness was measured by holding
the tablet diametrically between mobile and ﬁxed surface of
tester and then indicator scale was set to zero. Subsequently
the force (kg/cm2) was applied gradually to forward move of
the screw knob until tablet breaks.
2.2.3.4. Friability. Friability of tablets from each batch
(GMR1 to GMO3) was determined using Roche friabilator
(Electrolab, Mumbai, Maharashtra, India). Pre-weighed sam-
ple of randomly selected 10 tablets was subjected to friability
testing by transferring it into a plastic chamber rotating for a
total of 100 revolutions at 25 rpm for 4 min. This resulted into
the tablet drop across the height of 6 in. in each revolution
with the combined effect of shock and abrasion (USPNF,
2006a). Subsequently tablets were de-dusted for removal of
ﬁnes adhered to the tablet surface during the test and
reweighed. Friability (F) was then calculated using Eq. (1).
Each batch (GMR1 to GMO3) was evaluated in triplicate




where Wi and Wf are the initial and ﬁnal tablet weights.
Selected tablet sample passes the friability test if not more than
1% weight loss was observed (USPNF, 2006a).
2.2.3.5. Uniformity of thickness and diameter. By using digital
vernier calliper the crown-to-crown thickness and diameter
of minimum three tablets selected randomly from each batch
were measured at 3 different points of each tablet. The varia-
tion limits for both thickness and diameter of tablets allowed
are ±5% of the tablet size (Banker and Anderson, 1987).
2.2.3.6. In vitro drug release kinetics. Dissolution testing for all
tablet formulations (GMR1 to GMO3) of GLMP was per-
formed as per the procedure described in the individual
S1918 V.L. Gaikwad et al.monograph USP (USPNF, 2011) and in General Chapter
Dissolution Æ711æ, USP (USPNF, 2006b) as described below.
Prepared tablets (400 ± 5 mg) from all formulation batches
were evaluated in triplicate for in vitro drug release kinetics by
using USP Type-II (paddle method) dissolution test apparatus
(Electrolab, TDT 08L, Mumbai, Maharashtra, India).
Dissolution medium used was hydrochloric acid buffer pH
1.2 USP (900 mL) for ﬁrst 2 h, which was further replaced
by phosphate buffer pH 6.8 USP (900 mL), both maintained
at 37.5 ± 0.5 C (Sahu, 2010; USPNF, 2006b). Paddle speed
was set constant at 75 rpm (USPNF, 2011). At predetermined
time intervals, aliquots of 5 mL were withdrawn and sink con-
dition was maintained by replacing the withdrawn quantity
with respective fresh dissolution media (37.5 ± 0.5 C). By
using Whatman cellulose ﬁlter paper no. 42 (retention of
2.5 lm particle size) collected aliquots were ﬁltered and ana-
lyzed spectrophotometrically (Shimadzu Corporation, UV-
1800, Japan) at 228 for pH 1.2 and 227 nm for pH 6.8
(Sahu, 2010).
2.2.3.7. In vitro drug transportability studies. In vitro drug
transportability studies across dialysis membrane (HiMedia
Laboratories Pvt. Ltd., Mumbai, Maharashtra, India) were
performed for all batches (GMR1 to GMO3) in triplicate by
using designed glass tube. Internal diameter of glass tube
was 22 mm with an area of 314 mm2 available for drug trans-
port divided into a total of 25 oriﬁces on the surface (each ori-
ﬁce with 4 mm internal diameter). Receiver compartment of
tube measures volume (capacity) about 17 mL. Dialysis mem-
brane was coiled around the external surface of the tube after
soaking the membrane for overnight in respective dissolu-
tion/receptor media. The glass tube with coiled membrane
around it was then introduced between the basket wall and
the paddle shaft of dissolution test apparatus containing disso-
lution media maintained at 37.5 ± 0.5 C. All other variables
(dissolution medium, total time period, set of temperature con-
ditions, paddle speed, sampling volume and time points) were
kept constant as speciﬁed under in vitro dissolution study.
Aliquots of 5 mL were taken at speciﬁed time intervals from
receptor medium (volume = about 17 mL) and subsequently
ﬁltered using Whatman cellulose ﬁlter paper no. 42. The ﬁl-
trates were then analyzed spectrophotometrically (Shimadzu
Corporation, UV-1800, Japan) at observed kmax and % drug
transport was calculated. Withdrawn quantity of media was
replaced with the same amount of respective fresh media main-
tained at identical temperature conditions.
2.2.4. QSPR model development
2.2.4.1. Calculation of descriptors. A builder module of the
Vlife MDS 4.2 commercial software was used to draw the
molecular models/structures of polymers. Further, Merck
Molecular Force Field was used for energy optimization or
minimization of the drawn structures until the value of root mean
square gradient reaches to 0.001 kcal/mol A˚. Subsequently, each
polymeric structure was subjected for the calculation of several
descriptors (P118) from diverse physicochemical sub-classes
such as Chi, Chiv, Chi Chain, Chiv Chain, Chain Path
count, Individual, Path Count, Cluster, Path Cluster, Kappa,
Element Count, Electrostatic, Distance based Topological,
Polar Surface Area, Hydrophobicity SlogpA, Hydrophobicity
SlogpK, Hydrophobicity XlogpA and Hydrophobicity XlogpK.These sub-classes consist of several descriptors as representative
of polymeric physicochemical properties that would serve as
the measure of interactions between polymer and dissolution
media along with other formulation components (drug and
excipients).
2.2.4.2. Selection of molecular descriptors. Moreover, descrip-
tors were selected by correlating dissolution data (t90%: time
required for 90% release of initial drug amount), transporta-
bility data (%T60min: percent of drug amount transported at
60 min) and related formulation properties with calculated
molecular descriptors (P118). Further invariable descriptors
showing insigniﬁcant correlation with dependent variable were
eliminated and a data set of 60 signiﬁcant descriptors so
obtained was again allowed for correlation analysis with the
response. This resulted into an estimation of the correlation
coefﬁcient of individual descriptor and further assisted in selec-
tion of the best set of descriptors with the most signiﬁcant cor-
relation. At the end of the process a total of 5 molecular
descriptors have been selected based on assessment of best cor-
relation and considerable impact shown by individual descrip-
tor on response under study.
2.2.4.3. Model development and validation for QSPR analysis.
The data set was divided into the training and test set mole-
cules after entering the percentage (70%) of training set mole-
cules by using Random data selection method in Vlife MDS
4.2 commercial software. Further QSPR model was developed
with the use of training set having known data of the response
(t90%, %T60min and related formulation properties).
Predictability of developed QSPR model was then assessed
by challenging the model against test set molecules (not
included in model generation).
2.2.4.4. Multiple linear regression (MLR) analysis. Commonly,
independent variables with signiﬁcant impact were preferred in
the model development process to yield most proﬁcient and
successful QSPR model. The practical use of the developed
model is based on its ability for replicating any variation in
polymeric design parameters on drug release or drug concen-
tration proﬁle (Siepmann and Siepmann, 2008; Siepmann
et al., 2000). Hence, the present investigation was aimed to
develop a highly predictive QSPR model through MLR anal-
ysis between 5 molecular descriptors (independent variables)
and t90%, %T60min and related formulation properties (depen-
dent variables) by using a 2D QSAR tool of Vlife MDS 4.2
commercial software. Several combinations of training and
test set molecules selected on random basis were tested to yield
a top promising QSPR model. From randomly generated dif-
ferent QSPR models through MLR analysis, a set of top 3
physicochemical sub-classes of descriptors showing best corre-
lation and signiﬁcant effect on response have been identiﬁed.
From these sub-classes, a set of not more than 5 descriptors
as independent variables were randomly selected and pro-
cessed through MLR analysis by user deﬁned variable selec-
tion method for generation of at least 4 QSPR equations or
regression models. Eventually from last 4 developed models,
a QSPR model with least standard error and best correlation
coefﬁcient was selected. Therefore, without real formulation
of a dosage form a QSPR model developed in such a way
has good predictive potential for formulation composition
Statistical signiﬁcance of polymeric physicochemical properties S1919for required characteristics and hence could have a pharma-
coeconomic impact on future research.
3. Results and discussion
The present study involves evaluation of GLMP (a model drug
from neutral category) tablet formulations prepared using 3
polymers from 3 different categories (extended, moderate
and immediate release). Then QSPR model was developed
through correlation analysis between the generated experimen-
tal data and the molecular descriptors calculated for polymers.
The developed model could have high predictability for char-
acteristics of GLMP tablet formulations and also could pro-
mote future formulation design trials. Though the present
study does not consider the modeling of parameters other than
hardness, friability, drug release and transportability proﬁles,
these other evaluated parameters could help to ensure the for-
mation of tablets with acceptable characteristics exhibiting
required rate of drug release under speciﬁed experimental
conditions.
3.1. Characterization of drug and excipients
3.1.1. Standard curve
Detection of kmax at 228 in hydrochloric acid buffer pH 1.2
USP and at 227 nm in phosphate buffer pH 6.8 USP con-
ﬁrmed GLMP molecule which is in good agreement with pre-
vious reports (Wagh et al., 2012; Sahu, 2010). A linearFigure 1 FTIR spectra of pure GLMP and tablet formulations
(GMR1 to GMO3).equation from calibration curve of GLMP indicated coefﬁcient
of correlation, slope and intercept as +0.9996, 0.0062 and
+0.1 in buffer pH 1.2, however as +0.9992, 0.0663 and
+0.013 in buffer pH 6.8, respectively.
3.1.2. FTIR studies
Identiﬁcation and conﬁrmation of GLMP were done by
observing characteristic peaks of pure GLMP in FTIR spec-
trum by using the KBr method (Fig. 1). Characteristic peaks
in the FTIR spectrum of pure GLMP were observed at
3374.82 and 3287.07 (NAH stretching for urea); 2981.13 and
2937.06 (CAH); 1705.36, 1703.67 and 1601.19 (>C‚O);
1674.76 (NAH bending); 1500–600 (CAH and ‚CAH bend-
ing); 1341.62 and 1155.23 (S‚O stretching vibration in sulfon-
amide group); 1346.48, 1078.93 and 1039.13 (CAN stretching
vibration). These peaks were identical with reported standard
peaks conﬁrming the molecule as 3-ethyl-2,5-dihydro-4-
methyl-N-[2-[4-[[[[(trans-4-methylcyclohexyl)-amino]carbonyl]
amino]sulfonyl]phenyl]ethyl] 2-oxo-1H-pyrrole-1-carboxamide
(IP, 2010a; USPNF, 2006c; Moffat et al., 2004).
Furthermore, all tablet formulations (GMR1 to GMO3)
have shown very less or negligible shifting of GLMP peaks
as observed in the FTIR spectra (Fig. 1) indicating no any
chemical or structural alteration in GLMP. Such a slight or
minute shifting observed in peak intensity could be related to
the polymer adsorption onto the surface of the drug.
Therefore tablet formulations of GLMP with selected excipi-
ents can be prepared without losing its potency.3.2. Evaluation of tablet formulations
Physical evaluation of all prepared tablet formulations
(GMR1 to GMO3) indicated zero defects with smooth surface,
odorless, ﬂat in shape and white in color. Furthermore, evalu-
ation of different post-compression parameters was completed
as discussed below.
3.2.1. Weight uniformity
Uniformity of weight indicated the values between
0.85 ± 0.65% and 0.84 ± 0.49% deviation (Table 2) from
an average weight of the tablets (400 ± 5 mg) for all formula-
tions (GMR1 to GMO3). It has been observed that the devia-
tion falls within the acceptable prescribed standards (±5%
deviation approved for 250 mg or more average weight) indi-
cating uniformity in tablet weight (IP, 2010b). This was asso-
ciated with the free ﬂowing property of granules, invariable
die ﬁlling and compression of tablets with constant hardness.
3.2.2. Drug content
All formulation batches (GMR1 to GMO3) showed unifor-
mity in content of GLMP ranging from 97.42 ± 3.67% to
104.86 ± 2.73% (Table 2) with adequate precision. The
observed GLMP content was within the acceptable ofﬁcial
standards which states that glimepiride tablets contain not less
than 90.0% and not more than 110.0% of the stated amount of
glimepiride, C24H34N4O5S (IP, 2010a; USPNF, 2011).
3.2.3. Hardness
Hardness for all tablet formulations (GMR1 to GMO3) was
observed within a narrow range of 4.20 ± 0.28 to
Table 2 Post-compression evaluation of GLMP compacts.a
Batch code Weight uniformity (% deviation) Drug content (%) Hardness (kg/cm2) Friability (%) Thickness (mm) Diameter (mm)
GMR1 0.84 ± 0.49 101.87 ± 1.82 4.50 ± 0.10 0.242 ± 0.033 4.13 ± 0.012 10.05 ± 0.006
GMR2 0.45 ± 0.56 100.31 ± 3.23 4.67 ± 0.34 0.171 ± 0.027 4.13 ± 0.020 10.06 ± 0.005
GMR3 0.72 ± 0.55 104.86 ± 2.73 4.20 ± 0.28 0.303 ± 0.022 4.14 ± 0.015 10.05 ± 0.005
GMB1 0.52 ± 0.58 100.71 ± 4.60 4.51 ± 0.19 0.231 ± 0.014 4.14 ± 0.006 10.06 ± 0.010
GMB2 0.56 ± 0.65 98.08 ± 4.26 4.65 ± 0.13 0.181 ± 0.021 4.13 ± 0.015 10.05 ± 0.012
GMB3 0.23 ± 0.65 99.85 ± 1.73 4.77 ± 0.57 0.153 ± 0.012 4.12 ± 0.021 10.06 ± 0.017
GMO1 0.04 ± 0.65 100.02 ± 5.96 4.70 ± 0.20 0.177 ± 0.019 4.13 ± 0.017 10.06 ± 0.012
GMO2 0.58 ± 0.64 101.82 ± 3.17 4.53 ± 0.21 0.217 ± 0.011 4.13 ± 0.006 10.06 ± 0.017
GMO3 0.85 ± 0.65 97.42 ± 3.67 4.83 ± 0.23 0.122 ± 0.018 4.12 ± 0.015 10.06 ± 0.020
a Indicates average ± SD (n= 3).
Figure 2 In vitro drug release kinetics from GMR1 to GMR3
formulations.
Figure 3 In vitro drug release kinetics from GMB1 to GMO3
formulations.
S1920 V.L. Gaikwad et al.4.83 ± 0.23 kg/cm2 indicating uniformity in tablet hardness
(Table 2). To withstand the mechanical shocks commonly
observed during the machine operations, packaging and trans-
portation, the tablets must be formulated with adequate hard-
ness as indicative of tablet strength showing better handling
characteristics. A tablet formulation with lowest hardness
(batch GMR3) showed minimum t90% attributed to the lesser
densiﬁcation associated with greater porosity that could have
facilitated the entry of dissolution medium and accordingly
faster drug release.
3.2.4. Friability
In the present study, an inverse relationship between hardness
and friability of tablets has been observed where friability for
all GLMP batches (GMR1 to GMO3) showed variation
between 0.122 ± 0.018% and 0.303 ± 0.022% (Table 2). All
tablet formulations pass the friability test as observed results
were within the reported ofﬁcial standards [not more than
1%] (USPNF, 2006a). Friability data for all formulations
(GMR1 to GMO3) were found to be in good agreement with
in vitro drug release studies and hardness associated with
improved handling characteristics.
3.2.5. Uniformity of thickness and diameter
Uniformity in thickness and diameter of tablets from all
batches (GMR1 to GMO3) has been observed within a narrow
range of 4.12 ± 0.015 to 4.14 ± 0.015 mm and 10.05 ± 0.005
to 10.06 ± 0.020 mm, respectively (Table 2). All observed
results for tablet dimensions were within the acceptable limits
(±5%) of tablet size.
3.2.6. In vitro drug release kinetics
Prepared GLMP compacts (GMR1 to GMO3) have been eval-
uated in triplicate for dissolution kinetics using USP Type-II
(paddle method) dissolution test apparatus. Dissolution data
obtained were further processed for estimation of the mecha-
nism of drug release by linear regression analysis to test the
goodness of ﬁt for different kinetic models such as Zero order,
First order, Hixson-crowell, Higuchi matrix or Korsmeyer-
peppas kinetics. In vitro drug release proﬁles and kinetic
parameters with regression data of GLMP tablet formulations
were presented in Figs. 2 and 3 and Table 3, respectively.
Korsmeyer-peppas kinetic model was observed as the best
ﬁt for GMR1 to GMB2 formulations (r= 0.9756–0.9894),however batches GMB3 to GMO3 showed zero order kinetics
(r= 0.9824–0.9991) as given in Table 3. Additionally, release
exponent (n) indicated super case-II transport (n> 1.0) type
of drug release mechanism from GMR1 to GMB2

























GMR1 0.9472 0.9916 0.9486 0.9335 0.9786 1.1991 Korsmeyer-
peppas
10 23.02 ± 3.01
GMR2 0.9222 0.9873 0.9753 0.9602 0.9894 1.8225 Korsmeyer-
peppas
12.8 15.95 ± 2.33
GMR3 0.8774 0.9843 0.9609 0.9577 0.9756 2.3468 Korsmeyer-
peppas
8.2 43.01 ± 3.78
GMB1 0.9538 0.9811 0.9817 0.9719 0.9828 1.1434 Korsmeyer-
peppas
251 24.18 ± 2.87
GMB2 0.9577 0.9976 0.9757 0.9947 0.9839 1.0095 Korsmeyer-
peppas
353 14.31 ± 2.19
GMB3 0.9824 0.9909 0.9769 0.9947 0.9723 1.1458 Zero order 282 17.18 ± 1.85
GMO1 0.9955 0.9706 0.9532 0.9819 0.9652 0.9686 Zero order 799 5.87 ± 1.05
GMO2 0.9991 0.9842 0.9736 0.9932 0.9945 1.1156 Zero order 700 6.84 ± 1.62
GMO3 0.9972 0.9839 0.9646 0.9899 0.9961 0.9572 Zero order 834 2.89 ± 0.69
a Where ‘r’ and ‘n’ are coefﬁcient of correlation and release exponent (Korsmeyer-peppas model), respectively.
b Indicates average ± SD (n= 3).
Statistical signiﬁcance of polymeric physicochemical properties S1921formulations [Table 3] (Siepmann and Siepmann, 2008; Costa
and Lobo, 2001; Grassi and Grassi, 2005; Korsmeyer et al.,
1983; Dash et al., 2010; Siepmann and Peppas, 2001). It has
been reported that formulation following Korsmeyer-peppas
kinetic is indicative of the involvement of more than one mech-
anism and/or unclear or unknown mechanism of drug release
(Costa and Lobo, 2001).
It has been observed that the type of polymer incorporated
has majorly contributed in deciding the rate of drug release in
immediate release formulations (GMR1 to GMR3).
Additionally, tablet hardness might have contributed in con-
trolling t90% to some extent (Tables 2 and 3) as observed with
GMR3 where lowest t90% (8.2 min) was associated with lower
hardness of the tablet. This was attributed to the highly cross-
linked structure of CPVP that allows entrapment of water
molecules to higher extent causing faster swelling of the matrix
with a net result of the faster GLMP release (Fig. 2).
Conversely, higher t90% (12.8 min) for batch GMR2 could be
related to the comparative poor wettability of CCS taking
the maximum time for tablet wetting together with reduced
contact between drug and dissolution medium with the net
result as a slower rate of drug release (Fig. 2). All immediate
release batches (GMR1 to GMR3) followed Korsmeyer-
peppas kinetics with super case-II transport (release exponent
n> 1.0) type of mechanism for GLMP release.
Formulation GMB2 from moderate release category
showed higher t90% (353 min) indicative of GLMP release at
slower rates (PEG 6000). Fig. 3 clearly illustrates the initial fas-
ter rate of GLMP release from batch GMB2, however, after
3 h a reduced rate of release has been observed attributed to
the formation of local highly viscous polymeric layer (PEG
6000) around the tablet surface that limits the rate of drug dif-
fusion in the dissolution medium. Batch GMB1 (ME15)
showed faster drug release (t90% = 251 min) than GMB2 and
GMB3 (Table 3 and Fig. 3) attributed to the more hydrophilic
nature of ME15. It has been observed that ME15 gets quickly
hydrated with the formation of an outer gelatinous layer creat-
ing a barrier in further wetting of tablet core with the net result
as reduced initial faster release rate (Fig. 3). After completehydration, the formed gel layer gets dissolved into the medium
with time which was replaced by inner continuous fresh gel
layer that further slows down the entry of medium into the
tablet core and allows drug release in a more controlled way
(Gafourian et al., 2007). If polymer (ME15) is thermodynam-
ically compatible with the dissolution medium it causes relax-
ation of polymeric chains upon contact with dissolution
medium that subsequently increases chain ﬂexibility with
volume expansion. As a result faster rate of drug release out
of polymeric matrix has been observed (Wu et al., 2005).
Drug diffuses from ME15 matrix speciﬁcally through swelling,
diffusion and erosion front formed as a result of contact
with the dissolution medium (Siepmann and Peppas, 2001).
Improvement in thickness of above 3 fronts with the time
further leads to increased path length for drug diffusion with
a net effect of reduced release rate for maximum time
(Colombo et al., 2000, 1999). Moreover, tablet formulation
GMB3 showed the initial slower rate of GLMP release attrib-
uted to comparative lower solubility of CMCS than GMB1
(ME15) and GMB2 (PEG 6000) that limits the availability
of drug to dissolution medium (Fig. 3). Previous researchers
have reported that drug release from any dissolvable polymer
majorly occurs through either swelling or dissolution or com-
bination of these two mechanisms (Tahara et al., 1995;
Efentakis and Buckton, 2002). Formulations GMB1 and
GMB2 indicated Korsmeyer-peppas model as best ﬁt with
super case-II transport (release exponent n> 1.0) mechanism
for drug release, however batch GMB3 followed Zero order
kinetics for release of GLMP from tablets (Table 3).
Among extended release formulations (GMO1 to GMO3),
batch GMO3 (ERS100) exhibited maximum t90% (834 min)
indicating drug release for extended time (Table 3 and
Fig. 3). This was attributed to pH independent swelling, insol-
ubility and lower permeability of polymer for dissolution med-
ium with a net effect of pH independent and time controlled
GLMP release. The low permeability and insolubility of
ERS100 was attributed to the presence of a limited number
of ammonium groups or salts that restricts the formation of
channels for entry of dissolution medium into the tablet core
S1922 V.L. Gaikwad et al.plus drug diffusion outside the matrix. Next to batch GMO3,
formulation GMO1 showed extended GLMP release
(t90% = 799 min) due to the highly hydrophobic nature of
EC10 with negligible wetting ability. However, tablet formula-
tion GMO2 containing HPC indicated comparatively faster
rate of GLMP release (t90% = 700 min) as shown in Fig. 3.
All formulations from extended release category (GMO1 to
GMO3) followed Zero order kinetics for release of GLMP
from tablets.
3.2.7. In vitro drug transportability studies
While performing the dissolution study, all tablet formulations
(batches GMR1 to GMO3) were simultaneously evaluated for
transportability proﬁles in triplicate using glass tube specially
designed for transportability studies. After applying dialysis
membrane on the external surface, the glass tube was placed
in a dissolution basket between the paddle shaft and wall of
the basket. After the release and subsequent dissolution from
tablet formulation, drug gets transported across the dialysis
membrane into the receiver compartment of the tube. This
approach results into simultaneous estimation of release and
transportability proﬁles. The data obtained were further ana-
lyzed for estimation of percent amount of drug transported
at 60 min from the plot of %T60min against time. Evaluation
parameters (%T60min) and transportability proﬁles for all
tablet formulations (GMR1 to GMO3) were presented in
Table 3 and Fig. 4, respectively.
Batches GMR1 to GMR3 (immediate release formulations)
exhibited the release rate dependent transportability proﬁles
where batch GMR3 (CPVP) showed a faster rate of drug
transport (%T60min = 43.01%, Table 3) due to the higher
availability of dissolved drug (Figs. 2 and 4). This was attrib-
uted to the highly crosslinked structure of CPVP that allows
entrapment of more amount of water with the net result as
higher chain relaxation with faster disintegration and drug
release. However, too high quantity of drug available for
transport at once could also result in steady or constant trans-
portability proﬁle due to the membrane pore sealing effect.
Tablet formulations with moderate drug release proﬁles
(batches GMB1 to GMB3) showed a gradual increase in the
transport rate of GLMP (Fig. 4). A comparative lower avail-
ability of drug released in dissolution media for transportFigure 4 In vitro transportability proﬁles from GMR1 to GMO3
formulations.across membrane resulted into faster rates of transport.
Batch GMB1 exhibited a faster transport of GLMP
(%T60min = 24.18%, Table 3) due to the hydrophilic nature
of ME15 having more afﬁnity for dissolution medium that
increases the thermodynamic activity of the drug in the mem-
brane with a net effect as increased drug release. Moreover, the
higher pKa (6.2 at 25 C) and lower water solubility
(0.004 mg/mL) of GLMP could result in retention of GLMP
in more unionized form that gets across the membrane more
easily and hence faster rate of drug transport (Table 3).
Extended release formulations (GMO1 to GMO3) also
showed rate of GLMP transport depends on the release pro-
ﬁle. The release of drug for extended time causes limited avail-
ability of drug for transport than membrane area and hence
results into a complete and fast transport of available quantity
as indicated by higher relative rate of transport compared to
release (Figs. 3 and 4). Formulation GMO3 (ERS100) exhib-
ited slower rate of drug transport (%T60min = 2.89%,
Table 3) than GMO1 and GMO2 (Fig. 4) due to the time con-
trolled release based on the concentration used in the formula-
tion. Moreover, batch GMO1 (EC10) also showed
transportability proﬁle matching with batch GMO3. This
was attributed to the highly hydrophobic nature of EC10 with
less afﬁnity for water or dissolution media with a net result of
thermodynamically reduced activity of the drug in the mem-
brane. This resulted in the reduced release and transport of
drug across the membrane. A slower rate of drug release from
extended compared to immediate and moderate release formu-
lations limits the availability of drug for transport and that
would not cease the membrane pores. This resulted in the
increased rate of transport relative to the release rate of the
drug from matrices indicating the inﬂuence of some other fac-
tors related to the drug such as log P on transportability
proﬁle.3.3. QSPR model development
Statistical or mathematical models have been developed with
an ability to quantify the drug release kinetics, transportability
proﬁle and related formulation properties from pharmaceuti-
cal products. QSPR model is selected on the basis of its accu-
racy and predictive ability for early estimation of response
under investigation, which could be helpful in the development
of new drug delivery systems (Siepmann and Peppas, 2001).
Consequently, developed models must be highly realistic way
with lower complexity issue for a number of variables consid-
ered in the model development process. Process for the devel-
opment of new model must be associated with comparison of
theoretical calculations with the observed results. However,
the limited applicability of developed models in the design of
different formulation systems could be related to the complex-
ity of models and ultimately on a number of variables consid-
ered (Siepmann and Siepmann, 2008).
Molecular models of polymers were drawn and energy min-
imized by using Vlife MDS 4.2 commercial software.
Subsequently, a number of molecular descriptors (P118) were
calculated for each polymeric structure and correlated with
formulation properties for selecting a set of descriptors with
good correlation. Development and validation of models were
completed by dividing the descriptors into training and test set
molecules. Ultimately, a set of not more than 5 best descriptors
Table 4 Regression analysis data from QSPR modeling of GLMP formulations.a
Sr.
No.
Name of parameter Regression coeﬃcient (relative coeﬃcient)
Hardness Friability t90% %T60min
1. r2 0.8981 0.9761 0.9741 0.8761
2. q2 0.4647 0.7017 0.7483 0.4134








4. Standard error ±0.0979 ±0.0136 ±89.0035 ±7.0358
5. Intercept +5.058 +0.149 285.711 +65.870
6. XAAverage Hydrophilicity +4.674 (+0.9661) – 53.268 (0.0259) –
7. VolumeCount +0.032 (+0.0066) – – –
8. SAMostHydrophobic Hydrophilic
Distance
+0.004 (+0.0008) +0.005 (+0.0420) – 0.992 (0.0864)
9. chiV4 0.108 (0.0223) – – –
10. kappa3 0.020 (0.0041) +0.005 (+0.0420) – –
11. H-AcceptorCount – 0.052 (0.4369) – –
12. slogp – 0.041 (0.3445) – –
13. chi0 – +0.016 (+0.1345) – –
14. H-DonorCount – – 28.063 (0.0137) –
15. XKMostHydrophobic – – +1727.322
(+0.8417)
–
16. XKMostHydrophobicHydrophilicDistance – – +35.483 (+0.0173) –
17. BalabanIndexJ – – +207.962
(+0.1013)
8.199 (0.7141)
18. smr – – – +0.217 (+0.0189)
19. kappa2 – – – (2.024 (0.1763)
20. XAHydrophobicArea – – – (0.050 (0.0044)
a Where r2 is calculated squared correlation coefﬁcient and q2 is predicted correlation coefﬁcient (at p< 0.05).
Statistical signiﬁcance of polymeric physicochemical properties S1923was selected as independent variables for MLR analysis
against response variable (t90%, %T60min and related formula-
tion properties). This resulted in the generation of a QSPR
model exhibiting high coefﬁcient of determination and mini-
mum standard error with potential predictability (Table 4).
3.3.1. Hardness
‘XAAverageHydrophilicity’ showed highest positive effect on
tablet hardness (relative coefﬁcient =+0.9661, Table 4). ‘X
AAverageHydrophilicity’ descriptor signiﬁes average hydro-
philic value on the vdW surface. This parameter would
enhance bonding of water with the binder polymer and other
excipients and hence the presence of a polymer having high
hydrophilic count on the vdW surface causes formation of
harder tablet with a net result of delayed disintegration of
the tablet and slower initial drug release.
‘VolumeCount’ descriptor also exhibited signiﬁcant posi-
tive impact on hardness (relative coefﬁcient =+0.0066,
Table 4). ‘VolumeCount’ descriptor signiﬁes volume of a com-
pound. This indicates the increased tablet hardness with incor-
poration of a polymer having high volume related to higher
compressibility and improved physical bonding with other
molecules that result in the formation of harder tablet.
Another descriptor ‘SAMostHydrophobicHydrophilicDist
ance’ exhibited least positive effect on tablet hardness (relative
coefﬁcient =+0.0008, Table 4). ‘SAMostHydrophobicHydr
ophilic-Distance’ descriptor signiﬁes distance between most
hydrophobic and hydrophilic point on the vdW surface that
indicates the net polarity index on polymer surface. The posi-
tive coefﬁcient of regression indicates increased distance
between two points with the reduction in net polarity that
leads to the formation of harder tablet.However, ‘chiV4’ showed a considerable negative impact
on tablet hardness (relative coefﬁcient = 0.0223, Table 4)
indicating decreased hardness/strength of the tablet in the pres-
ence of a polymer having high ‘chiV4’ property. ‘chiV4’
descriptor signiﬁes the atomic valence connectivity index
(order 4). Thus, multiple connectivity or branched polymeric
matrix would lead to a decrease in hardness and this inﬂuence
of the ‘chiV4’ descriptor is in agreement with the well accepted
and reported inﬂuence of branched polymers on tablet
hardness.
Another descriptor ‘kappa3’ also exhibited negative impact
on hardness (relative coefﬁcient = 0.0041, Table 4) as
indicative of reduced hardness with increase in shape index.
‘kappa3’ descriptor signiﬁes the third kappa shape index.
Higher index denotes more uniform particles with the poor
physical bonding that leads to reduction in hardness or
strength of the tablet.3.3.1.1. QSPR equation. A set of maximum 5 descriptors
(explanatory variables) based on their good correlation and
signiﬁcant impact on hardness (dependent variable) was
selected for generation of numerous QSPR models. Further,
a model exhibiting best correlation and minimal standard error
was selected for predicting tablet hardness (Eq. (2)).
Hardness ¼ þ4:674XAAverageHydrophilicityþ 0:032
 VolumeCount 0:108 chiV4 0:020
 kappa3þ 0:004
 SAMostHydrophobicHydrophilicDistance
þ 5:058 ð0:0979Þ ð2Þ
S1924 V.L. Gaikwad et al.Eq. (2) shows a statistical model developed for hardness
indicating signiﬁcant correlation between all 5 descriptors
and hardness of GLMP tablets (r2 = 0.8981) with lowest stan-
dard error (±0.0979) and mean response as +5.058 as shown
in Table 4. All independent variables have shown signiﬁcant
impact over tablet hardness as indicated by F-test (5.2874).
From squared correlation coefﬁcient, 89.81% of the change
in tablet hardness can be elucidated by the change in the 5
independent descriptors. Hence, hardness of tablet could be
signiﬁcantly predicted from polymeric properties by using the
developed model (Eq. (2)).
3.3.2. Friability
‘H-AcceptorCount’ showed a signiﬁcant negative impact on
tablet friability (relative coefﬁcient = 0.4369, Table 4) indi-
cating reduced friability with the incorporation of a polymer
having a high H-bond accepting ability. ‘H-AcceptorCount’
represents the number of hydrogen bond acceptor atoms.
High H-bond acceptor count is associated with improved
physical bonding with active pharmaceutical ingredient (API)
that results in increased hardness and reduced friability of
the tablet.
Another descriptor ‘slogp’ also exhibited negative impact
on tablet friability (relative coefﬁcient = 0.3445, Table 4).
‘slogp’ descriptor signiﬁes log of the octanol/water partition
coefﬁcient. The inverse relationship is indicative of the forma-
tion of harder tablet having lower friability with reduction in
polarity or the increase in hydrophobicity of polymers.
However, ‘kappa3’ and ‘SAMostHydrophobicHydrophilic
Distance’ both have indicated positive and equal impact on
tablet friability (relative coefﬁcient =+0.0420, Table 4).
‘kappa3’ descriptor signiﬁes third kappa shape index and ‘S
AMostHydrophobicHydrophilicDistance’ descriptor signiﬁes
the distance between most hydrophobic and hydrophilic points
on the vdW surface. Higher values of shape index descriptor
indicate increased regularity in particle shape, which further
decreases particle initial adjustment during compression, and
results into the formation of tablet with lower hardness or
greater friability. Similarly, increased distance between most
hydrophilic and hydrophobic points on the vdW surface
(‘SAMostHydrophobic-HydrophilicDistance’) also resulted in
increased tablet friability.
Another descriptor ‘chi0’ also showed the highest positive
impact on friability (relative coefﬁcient =+0.1345, Table 4).
‘chi0’ descriptor signiﬁes a retention index (zero order) derived
directly from gradient retention times. Increased friability has
been observed due to increase in retention index, which is also
a measure of relative hydrophobicity.
3.3.2.1. QSPR equation. Several QSPR models for predicting
tablet friability have been developed by selecting not more
than 5 descriptors (independent variables) based on their high
correlation and considerable effect over friability (response
variable). Ultimately, a model with high coefﬁcient and small-
est standard error was selected as given in Eq. (3).
Friability¼0:052H AcceptorCount 0:041 slogp
þ 0:005kappa3þ 0:016 chi0þ 0:005
SAMostHydrophobicHydrophilicDistance
þ 0:149ð0:0136Þ ð3ÞStatistical model developed for tablet friability (Eq. (3))
indicated a good correlation with all 5 polymeric properties
(r2 = 0.9761) with mean response as +0.149 and standard
error as ±0.0136 (Table 4). A signiﬁcant effect of all indepen-
dent variables on friability was indicated by F-statistics
(24.4556). From model 97.61% of the change in friability
can be described by the change in 5 explanatory variables.
Hence, developed model (Eq. (3)) can be used to study the
effect of individual variable over response as well as for quan-
titative prediction (q2 = 0.7017) of tablet friability based on
the calculated polymeric properties.
3.3.3. In vitro drug release proﬁle
‘H-DonorCount’ showed a signiﬁcant negative impact on t90%
of GLMP (relative coefﬁcient = 0.0137, Table 4) indicating
faster rate of drug release. ‘H-DonorCount’ represents the
number of hydrogen bond donor atoms (AOH and >NH)
in structure. Polymer with highest H-bond donor count allows
the formation of H-bonding with water molecules or dissolu-
tion media that releases the drug at a faster rate as observed
with hydrophilic polymer. The faster release rate was attribu-
ted to the improved polymer wetting and availability of the
drug to the dissolution media. Further, from dissolution pro-
ﬁle drug gets released in the controlled manner attributed to
the polymer and dissolution medium both competing simulta-
neously for the drug. The initial slower rate of drug release was
related to the H-bonding formed with polymer (good
‘H-DonorCount’) present in the close vicinity of drug at a
higher concentration than dissolution medium. Therefore,
‘H-DonorCount’ must be greatly considered for selection of
a polymer in designing a drug delivery system for desired
dissolution proﬁle.
Another descriptor ‘XAAverageHydrophilicity’ exhibited
highest negative impact on rate of GLMP release (relative
coefﬁcient = 0.0259, Table 4) indicating release of drug at
a faster rate in the presence of a polymer having high hydro-
philic value. ‘XAAverageHydrophilicity’ descriptor represents
an average hydrophilic value on the vdW surface. A polymer
having high hydrophilic character allows faster wetting and
makes drug easily available to medium for dissolution.
Hence, accelerated rate of drug release from formulation sys-
tem containing polymer with high hydrophilic property has
been observed.
However, ‘XKMostHydrophobic’ showed the highest posi-
tive impact on t90% of GLMP (relative coefﬁcient =+0.8417,
Table 4) indicating a slower rate of drug release in the presence
of a polymer having high hydrophobic character. ‘XKMostH
ydrophobic’ descriptor signiﬁes most hydrophobic value on
the vdW surface. Polymer with higher hydrophobic value
shows limited wetting and hence avoids further entry of disso-
lution media associated with decreased rates of drug release.
Moreover, ‘XKMostHydrophobicHydrophilicDistance’
descriptor also exhibited signiﬁcant positive impact on
GLMP release rate (relative coefﬁcient =+0.0173, Table 4)
signifying inverse relationship between rate of drug release
and hydrophobic character reﬂected by the distance between
most hydrophobic and hydrophilic points on polymer surface.
‘XKMostHydrophobicHydrophilicDistance’ descriptor signi-
ﬁes the distance between most hydrophobic and hydrophilic
points on the vdW surface. Polymer with greater distance
between two points is indicative of reduced polarity and hence
Statistical signiﬁcance of polymeric physicochemical properties S1925improved hydrophobic value. Accordingly reduced rate of
drug release associated with limited wetting of the polymer
has been observed.
Another descriptor ‘BalabanIndexJ’ also showed signiﬁcant
positive impact over t90% of GLMP (relative coefﬁ-
cient =+0.1013, Table 4) as indicative of drug release at a
slower rate. ‘BalabanIndexJ’ is a distance based topological
descriptor represented by Eq. (4),
J ¼ ðE=lþ 1Þ
X
ðdsi; dsjÞ ð4Þ
where E is the number of edges, l is the number of rings in a
molecule, and dsi, dsj is sum of the row i and j of the distance
matrix. This descriptor may be inﬂuencing the release proﬁle
due to the extent of the complementary shapes of the
hydrophobic and hydrophilic surfaces of the polymer under
study with respect to those of the API. This parameter would
thus inﬂuence accessibility of the solubilizing media to the API
which would be competing with the extent and strength of
intermolecular interactions between the polymer and the API.
3.3.3.1. QSPR equation. A data set containing a maximum of 5
descriptors as independent variables based on the good corre-
lation and signiﬁcant effect over t90% of GLMP (response vari-
able) was selected for the development of a several models for
predicting dissolution proﬁle. A model with high squared cor-
relation coefﬁcient and low standard error was further selected
(Eq. (5)).




 285:711 ð89:0035Þ ð5Þ
Eq. (5) and Table 4 give a set of polymeric descriptors that
have contributed signiﬁcantly in determining the GLMP
release proﬁles from tablet formulations (batch GMR1 to
GMO3). Coefﬁcient of determination (r2 = 0.9741, Table 4)
indicated a very good correlation between all selected descrip-
tors and t90% of GLMP formulations. Therefore, 97.41% of
the change in t90% can be explained by the change in the 5
explanatory descriptors. The developed QSPR model showed
overall mean response or intercept as 285.711 and minimal
standard error (±89.0035). Also, predicted coefﬁcient
(q2 = 0.7483, Table 4) reﬂects the considerable predictability
of the model. F-statistics (22.5723) represented the signiﬁcant
effect of all 5 descriptors on t90% (Table 4). Hence, developed
model (Eq. (5)) could be used to predict the t90% of any neutral
drug based on the physicochemical properties of polymer inte-
grated in formulation system. The predicted values are in good
agreement with observed values for t90% in developed QSPR
model as shown in a plot of actual and predicted values
(Fig. 5). Additionally, the theoretical prediction of the formu-
lation composition for required release proﬁle of other neutral
drugs with acceptable precision could also be possible.3.3.4. In vitro drug transportability proﬁle
‘Smr’ showed the highest positive impact on %T60min (relative
coefﬁcient =+0.0189, Table 4). ‘Smr’ descriptor evaluates
molecular refractivity (including implicit hydrogens) which is
also a measure of molecular size and also is an atomiccontribution model that assumes the correct protonation state
(washed structures). Thus, this composite of properties, which
could be a measure of size as well as some types of non-bonded
interactions that the polymer would have with the drug as well
as the transport barrier, would evidently inﬂuence drug
transport.
However, ‘BalabanIndexJ’ showed the highest negative
impact on %T60min (relative coefﬁcient = 0.7141, Table 4)
indicating reduced rate of drug transport in the presence of a
polymer having high ‘BalabanIndexJ’. ‘BalabanIndexJ’ is a
distance based topological descriptors calculated by using
Eq. (4). The negative value of its coefﬁcient indicates reduced
transport of drug with an increase in the value of this descrip-
tor which is a measure of irregularity in shape of molecules of
the polymer which would directly inﬂuence with the drug and
the transport barrier. Alternatively the negative correlation to
transportability could mean that the increase in the shape
irregularity leads to increased interaction of the drug with
the polymer and hence limits the transport of the drug.
Another descriptor ‘kappa2’ also showed signiﬁcant nega-
tive impact over %T60min (relative coefﬁcient = 0.1763,
Table 4). ‘kappa2’ descriptor signiﬁes the second kappa shape
index: [(n  1)2/m2]. The negative coefﬁcient relates decreased
rate of drug transport with an increase in the shape
index/irregularity of polymeric particles that makes limited
availability of drug for dissolution and subsequent transport
across the membrane which is in good agreement with the
reported common theory together with previous results
reported under dissolution kinetics. ‘kappa2’ has also been a
shape index and the inﬂuence of this descriptor on the trans-
portability is found to be qualitatively similar to that of
‘BalabanIndexJ’ but both would serve as measures for differ-
ent domains accounting for shape. Increased interaction of
the polymer with the drug or decreased positive inﬂuence on
the increase in transportability of the drug through the interac-
tion of the polymer with the barrier may together be responsi-
ble for the negative contribution of this descriptor to
transportability.
Moreover, ‘SAMostHydrophobicHydrophilicDistance’
descriptor also exhibited signiﬁcant negative impact over
%T60min (relative coefﬁcient = 0.0864, Table 4). ‘SAMostH
ydrophobic-HydrophilicDistance’ descriptor signiﬁes the dis-
tance between most hydrophobic and hydrophilic points on
the vdW surface (by Audry method using Slogp). The negative
coefﬁcient indicates reduced transport of drug in the presence
of polymer with larger distances separating the most
hydrophobic and hydrophilic points on the VdW surface i.e.
reduction in net polarity index of the polymer. This was
accompanied by improved binding of drug with a complemen-
tary charge area over the surface of the polymer. This indicates
limited interactions of small polar water molecules per unit
surface area of polymer and hence results into longer wetting
time with slower rate of drug release and ultimately a reduc-
tion in drug transport.
Moreover, ‘XAHydrophobicArea’ indicated least negative
impact over %T60min (relative coefﬁcient = 0.0044,
Table 4) signifying reduced rate of GLMP transport in the
presence of a polymer having high hydrophobic surface area.
‘XAHydrophobicArea’ is a vdW surface descriptor showing
the hydrophobic surface area (by Audry method using
Xlogp). Polymer with highly hydrophobic surface area allows
limited contact with dissolution medium and hence wetting
Figure 5 Actual and predicted values for t90% and %T60min of GLMP tablet formulations.
S1926 V.L. Gaikwad et al.with drug release for an extended period of time. This limits
the availability of drug amount for transport with the net
result as reduced rates of transport which is in good agreement
with results observed for in vitro dissolution kinetics.
3.3.4.1. QSPR equation. Minimum of 4 QSPR models for pre-
dicting transportability proﬁle was generated by MLR analysis
of different sets of descriptors as independent variables and
%T60min as the dependent variable. From this, a model with





QSPR model developed (Eq. (6)) indicated a good correla-
tion (r2 = 0.8761) between polymeric properties and %T60min
with lowest standard error (±7.0358) and overall mean
response as +65.870. By using developed model 87.61% of
the change in %T60min can be described by the change in the
5 descriptors. Moreover, developed model has considerable
predictability for %T60min as indicated by predicted coefﬁcient
(q2 = 0.4134, Table 4). A signiﬁcant effect of selected poly-
meric descriptors on response was indicated by F-statistics
(coefﬁcient = 4.2437, Table 4).
QSPR models developed in such a way on the basis of a
comprehensive study of polymeric properties could help in
the quantitative prediction of the transportability proﬁle of
any neutral drug. Fig. 5 represents a plot of actual and pre-
dicted values for %T60min indicating a good agreement for
%T60min in the developed QSPR model. Such models could
also assist in the early prediction of the formulation composi-
tion for a desired transportability proﬁle.4. Conclusion
Developed QSPR models can be used for predicting the
release, transportability and other related formulation proper-
ties based on polymeric properties to be used in the unformu-
lated dosage form. Furthermore, predicting formulation
properties from other polymers exhibiting identical physico-
chemical properties could also be a possible outcome. Such
several serial investigations which are currently in progress
may lead to generation of models for predicting the composi-
tion of the formulation with required characteristics for each
chemical class of drugs. This approach would positively affect
the development of new formulation systems or optimization
of the existing one without expensive and time-consuming test-
ing in industrial research. Therefore, computer simulated
QSPR models would become integral part of future formula-
tion design trials in the pharmaceutical sector.
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